Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data
Lecanemab was generally well tolerated by most patients with early AD and treatment appeared to be more effective and safer in patients with low CSF-ptau181 levels. Our results suggest an association between lecanemab treatment and reduced markers of vascular endothelial injury.
Authors
- Kenjiro Ono (ORCID: https://orcid.org/0000-0001-8454-6155)
- Takahiro Yoshinobu
- Junji Komatsu (ORCID: https://orcid.org/0000-0002-5150-6322)
- Hiroki Yamaguchi (ORCID: https://orcid.org/0000-0003-2409-7401)
- Moeko Noguchi‐Shinohara (ORCID: https://orcid.org/0000-0003-2883-1773)
- Ayano Shima
- Yasuhiro Sakashita (ORCID: https://orcid.org/0000-0002-3284-3999)
- Yasutake Tada
- Taro Ozaki
- Tokuhei Ikeda
- Daiki Muramatsu (ORCID: https://orcid.org/0009-0009-5971-4538)
Institutions
- Kanazawa University (JP)
Publication Details
- Journal
- Alzheimer s Research & Therapy
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1186/s13195-025-01912-6
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00